Board meeting on Oct 26 to approve Q2 and H1 FY27 results

Profit growth above 25%EBITDA margin compressionExceptional itemResults View source PDF Explain this filing

ERIS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+1.8%Reaction day

₹1114.90

prior close

₹1120.40

announcement price

After-mkt

timing

Nifty Microcap 250market-2.6%+4.4% vs market

Pharmaceuticals peers, median of 172sector-1.7%+3.5% vs sector

On the reaction day the stock moved 4.4 pts more than Nifty Microcap 250 and 3.5 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.3

10m

+0.7

15m

+0.7

30m

+0.6

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+1.8-2.6+4.4-1.7+3.5

Next day

+0.4-3.6+4.0-2.2+2.6

-2.3-5.8+3.6-3.5+1.2

-1.3-5.5+4.1-2.4+1.1

+6.6-3.8+10.5-1.2+7.8

+5.3-3.8+9.1+0.1+5.2

+3.5-5.6+9.1-1.3+4.8

15d

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 172Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Eris Lifesciences has informed the exchanges that its Board of Directors will meet on Monday, October 26, 2026, to consider and approve the standalone and consolidated unaudited financial results for the quarter and half year ended September 30, 2026 (Q2 and H1 FY27). The trading window for insiders is already closed since October 1, 2026, and will reopen 48 hours after results are declared, per SEBI insider trading rules.

Likely market impact

Routine intimation. Investors should watch the October 26 results for revenue, margins, and profit trends in the pharma company.

By the numbersConsolidated · Q2 FY27 vs Q2 FY26

	Q2 FY27	Q2 FY26	Change
Revenue	₹892.4 Cr	₹792.4 Cr	+12.6%
Operating profit	₹189.5 Cr	₹169.6 Cr	+11.8%
Profit after tax	₹187.1 Cr	₹134.5 Cr	+39.2%
EBITDA margin	30.6%	36.4%	−5.7 pp

From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.